Navigation Links
Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment

The use of monoclonal anti-body (mAb) L2G7 could revolutionize treatment of Glioma, the most common type of primary brain tumor. Surgery, chemotherapy and radiation are the only available treatment options for this type of cancer. // However, there is a significant risk of physical inability and cognitive impairment associated with these treatment forms. The results of the study can be found in the Clinical Cancer Research journal.

The anti-body was found to inhibit growth of the malignant glioma cells, inducing an attenuation of growth. Surprisingly, the survival rate was also extended. Following these promising findings, it is hoped that human clinical trials of the immunotherapy would be initiated soon.

Animal models (mice) were created to represent human models of the malignant disease by Dr. Jin Kim (Galaxy Biotech) and Dr. John Laterra (Kennedy Krieger Institute). A study was then devised to test the effectiveness and safety of the monoclonal anti-body in the glioma treatment. Implantation of L2G7 under the skin was found to produce complete inhibition of the tumor while better results (tumor inhibition, tumor regression and enhanced survival rate) were seen following implantation in the brain.

The novel monoclonal anti-body, developed by Dr. Kim and his research team targeted the inhibition of hepatocyte growth factor (HGF), believed to play a major role in the further growth and spread of cancer by accelerating cell division, inducing formation of blood vessels and increasing resistance to chemotherapy drugs. The successful incorporation of the antibody, surpassing the 'blood-brain barrier' (BBB) proved to be a challenging task for the researchers.

Mice were treated with either L2G7 or a placebo, the results of which turned to be in favor of the monoclonal antibody, probably due to its specificity. The main advantage of this treatment modality is that it minimizes chances of neighboring tissue damage and the side effects.

Brain tumors account for significant mortality in children below 20 years of age. Conventional therapies have a very limited role to play in the treatment of brain tumors. The researchers have expressed hope over extrapolating the above finding which has already been proved successful in the treatment of lung, breast and colon cancer.


'"/>




Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal antibodies show promise in treatment of blood cancer
3. Monoclonal Antibody based system for Anthrax detection
4. Monoclonal Antibody Reduces Exacerbations in Asthmatics
5. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
6. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
7. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
8. Heart Stem Cells Could Revolutionize Cardiac Disease Therapy
9. Bio-Functional Garments That Could Revolutionize Fashion Industry
10. New Technique Could Revolutionize Melanoma Diagnosis and Treatment
11. Azathioprine Can Soon Revolutionize Eczema Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/5/2016)... ... 05, 2016 , ... Qrono Inc. , a specialty ... collaboration with the Australian critical medicine company, Phebra Pty Ltd. , to ... medicines can offer improved therapeutic benefits over oral formulations, including better bioavailability, improved ...
(Date:5/5/2016)... West Palm Beach, Fla. (PRWEB) , ... May 05, 2016 , ... ... New Vision Institute in San Diego, California. The laser eye center will now be ... Schanzlin’s recognized surgeons and attentive staff will remain at the full-service facility to ensure ...
(Date:5/5/2016)... Stockholm/San Jose (PRWEB) , ... May 05, 2016 , ... ... the art of self-love. Every day, LELO fans reach out via email, social media ... recurring question keeps upcoming up: “Is the way I masturbate ‘normal’ or ‘correct’?” , ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:5/5/2016)... ... May 05, 2016 , ... Vitenas Cosmetic Surgery has been named as one ... American Institute of Architects and the Academy of Architecture for Health. The building, brainchild ... Architects, opened to patients in October of 2014. , The prestigious ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocythemia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocythemia Market and ... comprehensive insights into Thrombocythemia pipeline products, ...
(Date:5/5/2016)... , May 5, 2016 ... of the  "Europe Thalassaemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Thalassaemia Market and Competitive Landscape Highlights - ... products, Thalassaemia epidemiology, Thalassaemia market valuations and ...
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
Breaking Medicine Technology: